Omnicell (NASDAQ:OMCL) EVP Sells $217,180.50 in Stock

Omnicell, Inc. (NASDAQ:OMCL) EVP Corey Manley sold 5,025 shares of Omnicell stock in a transaction on Monday, May 18th. The stock was sold at an average price of $43.22, for a total transaction of $217,180.50. Following the sale, the executive vice president owned 112,783 shares of the company’s stock, valued at $4,874,481.26. The trade was a 4.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Omnicell Stock Performance

Shares of NASDAQ:OMCL traded up $0.60 on Tuesday, hitting $43.82. 436,978 shares of the company were exchanged, compared to its average volume of 625,535. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. The stock’s 50 day moving average price is $37.66 and its 200 day moving average price is $40.50. The firm has a market capitalization of $1.99 billion, a P/E ratio of 99.59, a price-to-earnings-growth ratio of 1.12 and a beta of 0.96. Omnicell, Inc. has a 1-year low of $26.84 and a 1-year high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of $0.33 by $0.22. The business had revenue of $309.88 million for the quarter, compared to the consensus estimate of $304.02 million. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company’s quarterly revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.26 EPS. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. Sell-side analysts predict that Omnicell, Inc. will post 1.31 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Benchmark reiterated a “buy” rating on shares of Omnicell in a research note on Friday, March 13th. Wells Fargo & Company boosted their price target on Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research note on Thursday, April 23rd. Craig Hallum reiterated a “buy” rating and set a $55.00 price target on shares of Omnicell in a research note on Wednesday, April 29th. Weiss Ratings upgraded shares of Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Finally, Piper Sandler restated an “overweight” rating and set a $49.00 target price (down from $63.00) on shares of Omnicell in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $59.86.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new position in Omnicell during the second quarter valued at $26,000. First Horizon Corp acquired a new position in Omnicell during the third quarter valued at $31,000. Clearstead Advisors LLC lifted its position in Omnicell by 12,180.0% during the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company’s stock valued at $56,000 after purchasing an additional 1,218 shares during the period. Kemnay Advisory Services Inc. acquired a new position in Omnicell during the fourth quarter valued at $58,000. Finally, Parkside Financial Bank & Trust lifted its position in Omnicell by 1,708.1% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company’s stock valued at $61,000 after purchasing an additional 1,264 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.